Augmentation of cell-mediated cytotoxicity against renal carcinoma cells by recombinant interleukin 2.
The effects of recombinant interleukin 2 (IL-2) on natural killer (NK) cell activity against established renal carcinoma cell lines CaKi 1, KU-2, and freshly prepared renal carcinoma cells were studied. Augmentation of NK cell activity by IL-2 was dose- and time-dependent. The results indicate that the optimal dose of IL-2 was 100 to 500 U/mL, and that cytotoxicity increased significantly even at a low concentration such as 4 U/mL. IL-2 induced significantly higher levels of cytotoxicity against renal carcinoma cells than did gamma-interferon. The influence of IL-2 on lymphocyte subpopulations was then examined using flow cytometry with monoclonal antibodies OKT3, OKT4, OKT8, Leu 7, and Leu 11. The results showed that IL-2 increased the number of cells positive to Leu 11, the so-called active NK cells. We concluded that IL-2 has an important role in the treatment of renal carcinoma.
D002292:Carcinoma, Renal Cell / Q000276:immunology*; D002460:Cell Line; D003602:Cytotoxicity, Immunologic; D004306:Dose-Response Relationship, Immunologic; D006801:Humans; D007371:Interferon-gamma / Q000494:pharmacology; D007376:Interleukin-2 / Q000494:pharmacology*; D007680:Kidney Neoplasms / Q000276:immunology*; D007694:Killer Cells, Natural / Q000276:immunology*; D008214:Lymphocytes / Q000145:classification / Q000276:immunology; D011994:Recombinant Proteins
D007376:Interleukin-2; D011994:Recombinant Proteins; D007371:Interferon-gamma